Pharmaceutical & Cosmetic Raw Materials Supplier-OCTAGON CHEMICALS LIMITED
New Active Molecules

High Purity Tofacitinib 477600-75-2 (CP-690550)

Tofacitinib CP-690550 477600-75-2

Tofacitinib is used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.

Tofacitinib belongs to the janus kinase (JAK) inhibitor class and was firstly marketed as Xeljanz by Pfizer in USA in 2012 
for moderately to severely active rheumatoid arthritis in adults who are not responding well to Methotrexate. In 2018 Tofacitinib is approved in USA for treatment of moderately to severely active ulcerative colitis in adults.

Tofacitinib is currently under investigation for psoriasis. Tofacitinib has proved certain effectiveness for plaque psoriasis in Phase 3 randomized, controlled trials in comparison to placebo and to etanercept.

Chemical Facts of Tofacitinib (CP-690550,Tasocitinib):

Synonyms: 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile;CP 690550;3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-D)pyrimidin-4-yl-, (3R,4R)-;CP-690550(Tasocitinib,CP690550);CP 690550(Tasocitinib);Tasocitinib;3-((3R,4R)-4-Methyl-3-(Me...;Tasocitinib (CP 690550)
CAS: 477600-75-2
MF: C16H20N6O
MW: 312.3696


Chinese GMP Holder for Tofacitinib 477600-75-2: None.

CEP Holder for 
Tofacitinib 477600-75-2: None. (Tofacitinib was not approved by European regulatory agencies due to efficacy and safety concerns)
 
Disclaimer:Those products (High Purity Tofacitinib 477600-75-2) are for lab analytical & research purposes only.